Event Overview

Welcome to the Value-Driven Pharma Event

In the past, medical outcome-based pharmaceutical proposals generally have not materialized due to the level of complexity in administration. With payors seeking innovation that supports the ultimate goal of cost-reduction and better health for the patient, it is felt more than ever, that the primary goal of the relationship between manufacturer and payor should be aligning all of the incentives behind improving the health of individuals.

While drug companies have known for years that these outcomes-based pricing strategies are inevitable, developing those strategies and making them profitable have been the challenge. IIR’s Value-Driven Pharma Event brings together stakeholders across the healthcare value chain to engage in discussions evaluating the metrics being used by payors to determine a drug’s “value.”

At this premier conference, you will:

Discuss the unprecedented performance-based pricing agreement between CIGNA and Merck
Productively respond to the changing economics of drug “value” metrics to remain competitive
Demonstrate clinical and economic case for each product
Acquire insight on information payors are requiring from clinical trials
Understand where comparative effectiveness makes a difference in value
Develop new value-based pricing models and market partnerships
Communicate more effectively with public and private payors
Assess the impact of value-based drug design on manufacturers
Build absolute and comparative evidence to develop patient adherence
Utilize market data in early product development
Expedite development of personalized medicine
Increase product differentiation from R&D through commercialization